全球抗肥胖藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球抗肥胖藥物市場預計將從2025年的278.7億美元成長至2034年的3,279.2億美元，2026年至2034年的複合年成長率（CAGR）為31.51%。隨著製藥公司研發旨在幫助控制體重和治療肥胖這種慢性代謝紊亂的藥物，該市場正迅速擴張。人們對肥胖相關健康風險的認知不斷提高，以及藥物療法在臨床上的廣泛應用，都推動了市場需求。針對食慾和代謝途徑的現代療法備受關注，因為它們可以幫助合適的患者顯著減輕體重。此外，肥胖症診斷和治療的日益普及，也促使醫療專業人員和製藥公司加大對超越生活方式乾預的醫療方法的投入。

GLP-1及其相關療法的日益普及，以及新作用機制和劑型的不斷研發，都支撐著市場需求。口服療法、聯合治療和新一代藥物的研究正在不斷推進，旨在提高用藥的便利性、療效、耐受性和長期治療依從性。製藥公司也在加大投資，擴大產能以滿足不斷成長的需求。隨著人們越來越意識到肥胖是一種需要長期管理的疾病，這種認知正在影響著各大市場的臨床實踐、與保險公司的諮詢以及藥物研發策略。

未來前景將取決於臨床證據、治療可及性、定價、保險報銷、生產能力以及新療法的研發。研究日益聚焦於口服製劑、聯合治療、作用於多種代謝途徑的藥物。醫療保健系統將繼續專注於長期治療效果和成本效益。隨著更多產品進入研發和商業化階段，製藥公司之間的競爭預計也將加劇。隨著對肥胖症的科學認知不斷發展，代謝健康領域應用範圍的擴大可能會對市場產生進一步的影響。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它結合歷史趨勢、當前市場狀況和定量分析，揭示未來發展趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區特定分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗肥胖藥物市場：依作用機制分類

• 市場分析、洞察與預測
• GLP-1受體促效劑
• 雙重GIP/GLP-1促效劑
• 三重或多重受體促效劑
• 中樞性擬交感神經藥物
• 周邊脂肪酶抑制劑

第5章 全球抗肥胖藥物市場：依藥物類型分類

• 市場分析、洞察與預測
• 處方藥
• 成藥

第6章：全球抗肥胖藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 注射藥物（每週一次/每月一次）
• 口服片劑（每日一次）

第7章 全球抗肥胖藥物市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 線上藥局和遠端醫療平台
• 減重診所

第8章 全球抗肥胖藥物市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Altimmune Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim Intl. GmbH
  • Eli Lilly And Company
  • F. Hoffmann-La Roche AG
  • GSK Plc
  • Hanmi Pharm. Co. Ltd
  • Innovent Biologics Inc
  • Merck & Co. Inc
  • Novo Nordisk A/S
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Structure Therapeutics Inc
  • Takeda Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd

The global anti-obesity drugs market size is expected to reach USD 327.92 Billion in 2034 from USD 27.87 Billion in 2025, growing at a CAGR of 31.51% during 2026-2034.This market is expanding rapidly as pharmaceutical companies develop medicines designed to support weight management and address obesity as a chronic metabolic condition. Growing awareness of obesity-related health risks and increasing clinical use of pharmacological treatments are supporting demand. Modern therapies that target appetite and metabolic pathways have attracted substantial attention because they can produce meaningful weight reduction in appropriate patients. Increasing diagnosis and treatment of obesity are also encouraging healthcare providers and pharmaceutical companies to invest in medical approaches beyond lifestyle interventions alone.

Demand is being supported by the expanding use of GLP-1 and related therapies, alongside ongoing development of new mechanisms and formulations. Oral treatments, combination therapies, and next-generation medicines are being investigated to improve convenience, effectiveness, tolerability, and long-term treatment adherence. Pharmaceutical companies are also investing in manufacturing capacity as demand increases. The broader recognition of obesity as a condition requiring long-term management is influencing clinical practice, payer discussions, and pharmaceutical development strategies across major markets.

Future prospects will depend on clinical evidence, treatment accessibility, pricing, reimbursement, manufacturing capacity, and the development of additional therapies. Research is increasingly focused on oral formulations, combination approaches, and medicines that may address multiple metabolic pathways. Healthcare systems will continue evaluating long-term treatment outcomes and cost considerations. Competition among pharmaceutical developers is also expected to increase as more products enter development and commercialization. Expansion into broader metabolic-health applications could further influence the market as scientific understanding of obesity continues to evolve.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Mechanism of Action

• GLP-1 Receptor Agonists
• Dual GIP/GLP-1 Agonists
• Triple or Multi-Receptor Agonists
• Centrally Acting Sympathomimetics
• Peripherally Acting Lipase Inhibitors

By Drug Type

• Prescription Drugs
• OTC Drugs

By Route of Administration

• Injectable (Weekly / Monthly)
• Oral Daily Pills

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies & Tele-Health Platforms
• Weight-Loss Clinics

COMPANIES PROFILED

• Altimmune Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim Intl. GmbH, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hanmi Pharm. Co. Ltd., Innovent Biologics Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., Structure Therapeutics Inc., Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTI-OBESITY DRUGS MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 4.2. GLP-1 Receptor Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dual GIP/GLP-1 Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Triple or Multi-Receptor Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Centrally Acting Sympathomimetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Peripherally Acting Lipase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTI-OBESITY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Prescription Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. OTC Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTI-OBESITY DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Injectable (Weekly / Monthly) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Daily Pills Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTI-OBESITY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies & Tele-Health Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Weight-Loss Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTI-OBESITY DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Mechanism Of Action
  • 8.2.2 By Drug Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Mechanism Of Action
  • 8.3.2 By Drug Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Mechanism Of Action
  • 8.4.2 By Drug Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Mechanism Of Action
  • 8.5.2 By Drug Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Mechanism Of Action
  • 8.6.2 By Drug Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTI-OBESITY DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Altimmune Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 AstraZeneca Plc
  • 10.2.4 Bayer AG
  • 10.2.5 Boehringer Ingelheim Intl. GmbH
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 F. Hoffmann-La Roche AG
  • 10.2.8 GSK Plc
  • 10.2.9 Hanmi Pharm. Co. Ltd
  • 10.2.10 Innovent Biologics Inc
  • 10.2.11 Merck & Co. Inc
  • 10.2.12 Novo Nordisk A/S
  • 10.2.13 Pfizer Inc
  • 10.2.14 Rhythm Pharmaceuticals Inc
  • 10.2.15 Structure Therapeutics Inc
  • 10.2.16 Takeda Pharmaceutical Co. Ltd
  • 10.2.17 Teva Pharmaceutical Industries Ltd